Yan Gao1,2, Jacson Shen2, Edwin Choy2, Henry Mankin2, Francis Hornicek2, Zhenfeng Duan3. 1. Department of Clinical Laboratory Diagnostics, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. 2. Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom St, Jackson 1115, Boston, MA, 02114, USA. 3. Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom St, Jackson 1115, Boston, MA, 02114, USA. zduan@mgh.harvard.edu.
Abstract
PURPOSE: Overexpression of cyclin-dependent kinase (CDK) 4 has been observed in a variety of cancers and has been found to contribute to tumor cell growth and proliferation. However, the effect of inhibition of CDK4 in ovarian cancer is unknown. We investigated the therapeutic effect of the CDK4 inhibitor palbociclib in combination with paclitaxel in ovarian cancer cells. METHODS: Cell viabilities were determined by MTT assay after exposure to different dosages of palbociclib and/or paclitaxel. Western blot, immunofluorescence, and Calcein AM assays were conducted to determine the mechanisms underlying the cytotoxic effects of palbociclib in combination with paclitaxel. CDK4 siRNA was used to validate the outcome of targeting CDK4 by palbociclib in ovarian cancer cells. RESULTS: We found that combinations of palbociclib and paclitaxel significantly enhanced drug sensitivity in both Rb-positive (SKOV3TR) and Rb-negative (OVCAR8TR) ovarian cancer-derived cells. When combined with paclitaxel, palbociclib induced apoptosis in both SKOV3TR and OVCAR8TR cells. We also found that palbociclib inhibited the activity of P-glycoprotein (Pgp), and that siRNA-mediated CDK4 knockdown sensitized multidrug resistant (MDR) SKOV3TR and OVCAR8TR cells to paclitaxel. CONCLUSIONS: Inhibition of CDK4 by palbociclib can enhance paclitaxel sensitivity in both Rb-positive and Rb-negative MDR ovarian cancer cells by increasing apoptosis. CDK4 may serve as a promising target in the treatment of ovarian cancer.
PURPOSE: Overexpression of cyclin-dependent kinase (CDK) 4 has been observed in a variety of cancers and has been found to contribute to tumor cell growth and proliferation. However, the effect of inhibition of CDK4 in ovarian cancer is unknown. We investigated the therapeutic effect of the CDK4 inhibitor palbociclib in combination with paclitaxel in ovarian cancer cells. METHODS: Cell viabilities were determined by MTT assay after exposure to different dosages of palbociclib and/or paclitaxel. Western blot, immunofluorescence, and Calcein AM assays were conducted to determine the mechanisms underlying the cytotoxic effects of palbociclib in combination with paclitaxel. CDK4 siRNA was used to validate the outcome of targeting CDK4 by palbociclib in ovarian cancer cells. RESULTS: We found that combinations of palbociclib and paclitaxel significantly enhanced drug sensitivity in both Rb-positive (SKOV3TR) and Rb-negative (OVCAR8TR) ovarian cancer-derived cells. When combined with paclitaxel, palbociclib induced apoptosis in both SKOV3TR and OVCAR8TR cells. We also found that palbociclib inhibited the activity of P-glycoprotein (Pgp), and that siRNA-mediated CDK4 knockdown sensitized multidrug resistant (MDR) SKOV3TR and OVCAR8TR cells to paclitaxel. CONCLUSIONS: Inhibition of CDK4 by palbociclib can enhance paclitaxel sensitivity in both Rb-positive and Rb-negative MDR ovarian cancer cells by increasing apoptosis. CDK4 may serve as a promising target in the treatment of ovarian cancer.
Authors: John P Leonard; Ann S LaCasce; Mitchell R Smith; Ariela Noy; Lucian R Chirieac; Scott J Rodig; Jian Q Yu; Shankar Vallabhajosula; Heiko Schoder; Patricia English; Donna S Neuberg; Peter Martin; Michael M Millenson; Scott A Ely; Rachel Courtney; Naveed Shaik; Keith D Wilner; Sophia Randolph; Annick D Van den Abbeele; Selina Y Chen-Kiang; Jeffrey T Yap; Geoffrey I Shapiro Journal: Blood Date: 2012-03-01 Impact factor: 22.113
Authors: Kristina Goetze; Christian G Fabian; Andrea Siebers; Livia Binz; Daniel Faber; Stefano Indraccolo; Giorgia Nardo; Ulrike G A Sattler; Wolfgang Mueller-Klieser Journal: Cell Oncol (Dordr) Date: 2015-08-19 Impact factor: 6.730
Authors: Thanh U Barbie; David A Barbie; David T MacLaughlin; Shyamala Maheswaran; Patricia K Donahoe Journal: Proc Natl Acad Sci U S A Date: 2003-12-11 Impact factor: 11.205
Authors: Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman Journal: Nat Rev Drug Discov Date: 2006-03 Impact factor: 84.694
Authors: Sandeep Rana; Smit Kour; Yogesh A Sonawane; Caroline M Robb; Jacob I Contreras; Smitha Kizhake; Muhammad Zahid; Adam R Karpf; Amarnath Natarajan Journal: Chem Biol Drug Des Date: 2020-04-22 Impact factor: 2.817
Authors: Andrea M Pesch; Nicole H Hirsh; Anna R Michmerhuizen; Kassidy M Jungles; Kari Wilder-Romans; Benjamin C Chandler; Meilan Liu; Lynn M Lerner; Charles A Nino; Connor Ward; Erin F Cobain; Theodore S Lawrence; Lori J Pierce; James M Rae; Corey W Speers Journal: JCI Insight Date: 2022-02-08
Authors: Andrea M Pesch; Nicole H Hirsh; Benjamin C Chandler; Anna R Michmerhuizen; Cassandra L Ritter; Marlie P Androsiglio; Kari Wilder-Romans; Meilan Liu; Christina L Gersch; José M Larios; Lori J Pierce; James M Rae; Corey W Speers Journal: Clin Cancer Res Date: 2020-09-23 Impact factor: 12.531